Ticagrelor Use in Stroke Patients: Past, Present, and Future

Vasc Health Risk Manag. 2021 Jun 15:17:357-362. doi: 10.2147/VHRM.S266968. eCollection 2021.

Abstract

Antiplatelet medications are the mainstay for secondary stroke treatment. Aspirin, clopidogrel, and aspirin-dipyridamole are commonly used antiplatelet medications. Other antiplatelet medications such as ticagrelor and prasugrel have been majorly used in cardiovascular or neuro-interventional specialties. Recent studies have paved a way to their use in secondary stroke prevention. In this review, we have briefly discussed the pharmacology of ticagrelor, published literature in cardiology and stroke trials, use of ticagrelor among patients with ischemic strokes, and compared its efficacy, limitations and side-effects with other antiplatelet medications.

Keywords: Ticagrelor; clopidogrel; platelet inhibition; stroke.

Publication types

  • Review

MeSH terms

  • Hemorrhage / chemically induced
  • Humans
  • Ischemic Stroke / blood
  • Ischemic Stroke / diagnosis
  • Ischemic Stroke / drug therapy*
  • Ischemic Stroke / mortality
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Risk Assessment
  • Risk Factors
  • Secondary Prevention*
  • Ticagrelor / adverse effects
  • Ticagrelor / therapeutic use*
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Ticagrelor

Grants and funding

This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.